Fig. 6From: Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis - a six month phase II randomized study with 24 months of follow-upThere was no significant difference between the treatment and control groups in terms of no disease progression rate (measured by time to rescue therapy) over the 24 month duration of the study. P > 0.05Back to article page